In AML, the CD34+ CD38- stem-like subpopulation display a lower expression of FAS and FAS ligand (FAS-L) than CD38+ differentiated cells, triggering chemoresistance (36, 37). This evidence concerns the gene CD34 and acute myeloid leukemia.